A Surrey, England-based company offering software to help manage large drug studies has received an undisclosed equity investment from Albion Ventures.

Cisiv received the investment recently, according to a release from Albion. The company's Baseline Plus software allows drug companies to track data in long-term studies on licensed medicines. Cisiv's business model is designed to exploit a rapidly growing area of drug research based on newly developing regulatory requirements.

Albion has now made four investments in health care IT, including three this year alone.